Cosmetics | FDA
FDA updated its cosmetics page to highlight allergen risks, including temporary henna tattoos and fragrance allergens, reinforcing MoCRA compliance requirements for allergen labeling and safety substantiation.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Indie beauty brands, contract manufacturers, private-label makers, importers/distributors should confirm how it applies to their specific situation before acting. There is a time constraint attached: Ongoing; MoCRA compliance deadlines for allergen labeling are already in effect or phased in by 2024-2025.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA spotlighted allergens in cosmetics, emphasizing existing MoCRA requirements for fragrance allergen labeling and safety substantiation.
Who it affects
Indie beauty brands, contract manufacturers, private-label makers, importers/distributors
What you must do
Review product formulations for known allergens (e.g., fragrance mix, preservatives) and ensure labeling complies with MoCRA allergen disclosure rules.
Deadline
Ongoing; MoCRA compliance deadlines for allergen labeling are already in effect or phased in by 2024-2025.
Source: https://www.fda.gov/cosmetics
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection